Authors: Martha Powell, Future Science Group
Despite there being many combinations of antiretrovirals that can be given as single, daily pills, there is a need for long-acting formulations for HIV. These would simplify the regimen for HIV treatment further and might also aid some of the challenges surrounding health privacy and the stigma felt but people living with HIV, as treatment would be required less frequently.
In addition, with the advent of pre-exposure prophylaxis, this represents another area whether long-acting formulations could be beneficial, therefore posing an advantage for both prevention and treatment of HIV.
In this infographic we provide a visual snapshot of the long-acting HIV formulations currently in the clinical pipeline, waiting for approval or already in use in specific countries.